Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib, Dasatinib, and Dexamethasone in Ph+ ALL
NCT02494882Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2015
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Clinical response at 2 years. Started Jun 2015; status: active, not recruiting.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02494882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494882.